Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Rigel Pharmaceuticals Inc. | REZLIDHIA (olutasidenib) - (CONNECT) | High-grade glioma (HGG) harboring an isocitrate dehydrogenase-1 (IDH1) mutation | Phase 2 | Data Released | Oral | Oncology |
| Rigel Pharmaceuticals Inc. | Fostamatinib (NIH/NHLBI-sponsored) | COVID-19 | Phase 2 | Ongoing | Oral | COVID-19 |
| Rigel Pharmaceuticals Inc. | R348 | Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease (GvHD) | Phase 2 | Trial Completed | Topical ophthalmic | Opthalmic |
| Rigel Pharmaceuticals Inc. | TAVALISSE (Fostamatinib) | IgA nephropathy | Phase 2 | Trial Discontinued | Oral | #N/A |
| Roche Holding AG ADR | ESBRIET (pirfenidone) | Unclassifiable interstitial lung disease (UILD) | PDUFA priority review | Oral | Respiratory | |
| Roche Holding AG ADR | Polivy (polatuzumab vedotin-piiq) in combination with Rituxan | Diffuse Large B-Cell Lymphoma | BLA Filing | Intravenous | Oncology | |
| Roche Holding AG ADR | Crovalimab - (COMMODORE 1 + 2) | Paroxysmal nocturnal hemoglobinuria (PNH) | BLA Filing | Intravenous and subcutaneous | Hematology | |
| Roche Holding AG ADR | Ronapreve (REGEN-COV 2066) | COVID-19 (Anti-viral antibody) | BLA Filing | Trial Planned | Intravenous injection | COVID-19 |
